Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
05 Junho 2024 - 5:15PM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company developing novel, investigational engineered cytokine
therapies designed to address areas of unmet need for patients with
a variety of cancers, today announced that Caroline Loew, Ph.D.,
CEO, will present at the East Coast IDEAS Investor Conference on
June 13 at 9:15 a.m. EST. A webcast will be available at
www.threepartadvisors.com/east-coast and ir.muraloncology.com.
About IDEAS Investor Conferences
The mission of the IDEAS Conferences is to provide independent
regional venues for quality companies to present their investment
merits to an influential audience of investment professionals.
Unlike traditional bank-sponsored events, IDEAS Investor
Conferences are “SPONSORED BY INVESTORS. FOR INVESTORS” and for the
benefit of regional investment communities. Conference sponsors
collectively have more than $200 billion in assets under management
and include: 1102 Partners, Adirondack Research and Management,
Allianz Global Investors: NFJ Investment Group, Ariel Investments,
Aristotle Capital Boston, Ascend Wealth Advisors, Barrow Hanley
Mewhinney & Strauss, BMO Global Asset Management, Constitution
Research & Management, Inc., Diamond Hill, First Wilshire
Securities Management, Inc., Granahan Investment Management, Great
Lakes Advisors, Greenbrier Partners Capital Management, LLC, Hodges
Capital Management, Ironwood Investment Management, Keeley Teton
Advisors, Luther King Capital Management, Marble Harbor Investment
Counsel, North Star Investment Management, Perritt Capital
Management, Punch & Associates, Shepherd Kaplan Krochuk,
Westwood Holdings Group, Inc., and William Harris Investors. The
IDEAS Investor Conferences are held annually and are produced by
Three Part Advisors, LLC. Additional information about the events
can be located at http://www.IDEASconferences.com.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering
platform to develop cytokine-based immunotherapies for the
treatment of cancer. By combining our expertise in cytokine biology
and immune cell modulation and our protein engineering platform, we
are developing medicines to deliver meaningful and clinical
benefits to people living with cancer. Our mission is to
broaden the potential and reach of cytokine-based immunotherapies
to improve the lives of patients. Our lead candidate, nemvaleukin,
is currently in potentially registrational trials in mucosal
melanoma and platinum-resistant ovarian cancer. Mural Oncology has
its registered office in Dublin, Ireland, and its primary
facilities in Waltham, Mass. For more information, visit Mural
Oncology’s website at www.muraloncology.com and follow us on
LinkedIn and X.
Investors:David Borah,
CFAdavid.borah@muraloncology.com781-614-0060
Media:Katie
Sullivankatie.sullivan@muraloncology.com781-614-0034
Mural Oncology (NASDAQ:MURA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Mural Oncology (NASDAQ:MURA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024